## Child & Adolescent Psychiatry Alerts 2019 Self-Assessment Module 6: Peer Comparison

You recently participated in an ABPN-approved Self-Assessment activity relevant to your specialty and/or subspecialty. This peer comparison report provides you with feedback on your performance, relative to your peers, on the test module. In order to recognize your current knowledge base and to identify specific topics where further study may be needed, please review your answers to the following questions and compare them with those of your peers.

	Prevention Wide-ranging Online Data for Epidemiologic Research the >85,000 adolescent suicides recorded between 1975 and 2016
True	100.00 %
False	0.00 %
	icate a steady increase in annual rates of adolescent suicide that is rticularly large in, who experienced a >12% annual increase
Boys aged 10–14 years	0.00 %
Boys aged 15–19 years	0.00 %
Girls aged 10–14 years	100.00 %
Girls aged 15–19 years	0.00 %
3) According to a review, in adolescents with co- disorders should be integrated, and ma Fluoxetine monotherapy	occurring depression and substance use disorder treatment of the 2 y be the most effective option. $0.00\%$
Motivational enhancement therapy/CBT	100.00 %
Dialectical behavior therapy	0.00 %
Sertraline plus contingency management	0.00 %
	ions have become available for treatment of ADHD. Most of the -acting formulations and novel delivery systems, and new options swallowing have been introduced.  0.00 %
Chewable tablets	0.00 %
Suspensions/solutions	0.00 %
All of the above	100.00 %
5) New long-acting formulations of that delayed/extended release are now available.	t make use of microbead technology capable of both immediate and
Amphetamine only	0.00 %
Methylphenidate only	0.00 %
Both amphetamine and methylphenidate	100.00 %

0.00 %

None of the above

6) In addition, a transdermal methylphenidate patch (L	•	-
absorption continuing for several hours after patch ren		
methylphenidate are similar to other formulations, son formulation.	ne unique risks including	are associated with this
Local contact dermatitis	0.00 %	
Discomfort with patch removal	0.00 %	
Accidental poisoning	0.00 %	
All of the above	100.00 %	
All of the above	100.00 %	
7) A delayed release/extended release methylphenidat	e formulation (Jornav PM), which	uses a proprietary delivery
system containing microbeads with 2 layers of coating		
release in an extended pattern—is meant to be taken i		_
clinical action for up to 22–24 hours post-dose.		
2–3 hours	0.00 %	
6–8 hours	0.00 %	
8–10 hours	100.00 %	
>12 hours	0.00 %	
8) In a randomized controlled trial, the investigational	extended-release nonstimulant m	nedication viloxazine was
effective but poorly tolerated in children with ADHD.		
True	0.00 %	
False	100.00 %	
9) Viloxazine at 200, 300, and 400 mg/day was signific	antly superior to placebo at reduc	ing ADUD Bating Scale IV
total scores, but between-group differences on the		
Inattention	100.00 %	
Hyperactivity/impulsivity	0.00 %	
Tryper decivity, impulsivity	0.00 /0	
10) Although the study results are preliminary, they su	ggest that efficacy and tolerability	y of viloxazine appear to be
other nonstimulants used to treat ADHD.		
Better than	25.00 %	
Similar to	75.00 %	
Worse than	0.00 %	
11) According to the results of a case-control study, in y	roung woman with anarovia narv	aca usa of aral contracontinos
(OCs) appears to bone loss.	oung women with unorexia hervi	osa use of oral contraceptives
Reverse	50.00 %	
Limit	50.00 %	
Have no effect on	0.00 %	
That's his effect on	0.00 /0	
12) Although the favorable effects of OCs do not appear	r to completely offset the negativ	ve effects of anorexia nervosa
on bone tissue, the effects appear to be strong enough	that OCs can be used as the sole	method to protect bone in
women with the disorder.		
True	50%	
False	50%	